VALEANT PHARMACEUTICALS INTERNATIONAL TO ACQUIRE BAUSCH + LOMB FOR $8.7 BILLION

Valeant Pharmaceuticals International and Bausch + Lomb Holdings Incorporated have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash. Under the terms of the agreement, Valeant will pay $ 8.7 billion in cash, of which approximately $4.5 billion will go to an investor group led by Warburg Pincus and approximately $4.2 billion will be used to repay Bausch + Lomb's outstanding debt. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division. www.bausch.com